The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
Open accessAbstract
RAS proteins are important direct activators of p110α, p110γ, and p110δ type I phosphoinositide 3-kinases (PI3Ks), interacting via an amino-terminal RAS-binding domain (RBD). Here, we investigate the regulation of the ubiquitous p110β isoform of PI3K, implicated in G-protein-coupled receptor (GPCR) signaling, PTEN-loss-driven cancers, and thrombocyte function. Unexpectedly, RAS is unable to interact with p110β, but instead RAC1 and CDC42 from the RHO subfamily of small GTPases bind and activate p110β via its RBD. In fibroblasts, GPCRs couple to PI3K through Dock180/Elmo1-mediated RAC activation and subsequent interaction with p110β. Cells from mice carrying mutations in the p110β RBD show reduced PI3K activity and defective chemotaxis, and these mice are resistant to experimental lung fibrosis. These findings revise our understanding of the regulation of type I PI3K by showing that both RAS and RHO family GTPases directly regulate distinct ubiquitous PI3K isoforms and that RAC activates p110β downstream of GPCRs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 1×
“…the use of early passage primary p110b-RBD-DM MEFs. p110b-RBD-DM Mice Are Resistant to Bleomycin-Induced Lung Fibrosis Fibroblasts are motile cells with proposed key roles in the development and progression of a wide range of diseases, including cancer and fibrosis (Wynn and Ramalingam, 2012).”
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Self-citationThe emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Spatial and Temporal Regulation of 3-Phosphoinositides by PI 3-Kinase and PTEN Mediates Chemotaxis
Funamoto, S., Meili, R., Lee, S., Parry, L., & Firtel, R. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00755-9 · Cited by 751
Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K
Keely, P. J., Westwick, J. K., Whitehead, I. P., Der, C. J., & Parise, L. V. (1997) · Nature · doi:10.1038/37656 · Cited by 732
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688
Cited by
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Yu, J. S. L., & Cui, W. (2016) · Development · doi:10.1242/dev.137075 · Cited by 1,135
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
Rho GTPases: Regulation and roles in cancer cell biology
Haga, R. B., & Ridley, A. J. (2016) · Small GTPases · doi:10.1080/21541248.2016.1232583 · Cited by 559
PI3K signalling in inflammation
Hawkins, P. T., & Stephens, L. R. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.006 · Cited by 541
PI3K isoforms in cell signalling and vesicle trafficking
Bilanges, B., Posor, Y., & Vanhaesebroeck, B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0129-z · Cited by 525
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
Wang, J., Hu, K., Cai, X., Yang, B., He, Q., Wang, J., & Weng, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.023 · Cited by 450
Classes of phosphoinositide 3-kinases at a glance
Jean, S., & Kiger, A. A. (2014) · Journal of Cell Science · doi:10.1242/jcs.093773 · Cited by 379
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
PI3Kδ and primary immunodeficiencies
Lucas, C. L., Chandra, A., Nejentsev, S., Condliffe, A. M., & Okkenhaug, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.93 · Cited by 342
Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease
Burke, J. E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.005 · Cited by 276
Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249
Dock-family exchange factors in cell migration and disease
Gadea, G., & Blangy, A. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2014.06.003 · Cited by 217
Synergy in activating class I PI3Ks
Burke, J. E., & Williams, R. L. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.003 · Cited by 216
Mukai, J., Tamura, M., Fénelon, K., Rosen, A. M., Spellman, T. J., Kang, R., MacDermott, A. B., Karayiorgou, M., Gordon, J. A., & Gogos, J. A. (2015) · Neuron · doi:10.1016/j.neuron.2015.04.003 · Cited by 178
RAS mutations in human cancers: Roles in precision medicine
Murugan, A. K., Grieco, M., & Tsuchida, N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.007 · Cited by 146
Gross, C., & Bassell, G. J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00012 · Cited by 63
Zhou, Z.-W., Ambrogio, C., Bera, A. K., Li, Q., Li, X.-X., Li, L., Son, J., Gondi, S., Li, J., Campbell, E., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0448 · Cited by 60
PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma
Deuker, M. M., Marsh Durban, V., Phillips, W. A., & McMahon, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0856 · Cited by 60
Foster, P., Yamaguchi, K., Hsu, P. P., Qian, F., Du, X., Wu, J., Won, K.-A., Yu, P., Jaeger, C. T., Zhang, W., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0833 · Cited by 58
Yuzugullu, H., Baitsch, L., Von, T., Steiner, A., Tong, H., Ni, J., Clayton, L. K., Bronson, R., Roberts, T. M., Gritsman, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9501 · Cited by 47
Thibault, B., Ramos-Delgado, F., & Guillermet-Guibert, J. (2023) · Cancers · doi:10.3390/cancers15030784 · Cited by 40
Ho Wei, L., Arastoo, M., Georgiou, I., Manning, D. R., & Riobo-Del Galdo, N. A. (2018) · PLOS ONE · doi:10.1371/journal.pone.0203170 · Cited by 21
Ismail, M., Davies, G., Sproat, G., Monteverde, T., Tart, J., Acebrón-García-de-Eulate, M., Gohlke, A., Hancock, D., Adhikari, S., Stefanovic-Barrett, S., et al. (2024) · SLAS Discovery · doi:10.1016/j.slasd.2024.100197 · Cited by 6
Self-citationKilling Tumors by Keeping Ras and PI3′ Kinase Apart
Yuan, T. L., & McCormick, F. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.015 · Cited by 5
Duewell, B. R., Wilson, N. E., Bailey, G. M., Peabody, S. E., & Hansen, S. D. (2024) · eLife · doi:10.7554/elife.88991.3 · Cited by 2
Qu, Y., Wu, L., Wang, Y., Peng, F., Zhang, J., Pan, D., Wang, T., Zhou, Y., Xia, J., He, J., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.041
Duewell, B. R., Wilson, N. E., Bailey, G. M., Peabody, S. E., & Hansen, S. D. (2023) · doi:10.1101/2023.05.01.538969
Metadata
- Authors
- Fritsch, R., de Krijger, I., Fritsch, K., George, R., Reason, B., Kumar, M. S., Diefenbacher, M., Stamp, G., & Downward, J.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 153
- Issue
- 5
- Pages
- 1050-1063
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2134629247
- Cited by
- 306
- References
- 49
- FWCI
- 13.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.